A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2002
12/11/2002	CN1384877A Rescue of mumps virus from cDNA
12/11/2002	CN1384840A Antibody of human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin
12/11/2002	CN1384839A Redox reversible HCV proteins with native-like conformation
12/11/2002	CN1384758A Mutant human CD80 and copositions for and methods of making and using the same
12/11/2002	CN1384757A Method for down-regulating GDF-8 activity
12/11/2002	CN1384733A Dry powder compositions having improved dispersivity
12/11/2002	CN1384119A Composite yolk antibody for resisting fowl's viral blight and its prepn and application
12/11/2002	CN1095677C 化合物 Compound
12/10/2002	US6493637 Coincidence detection method, products and apparatus
12/10/2002	US6492497 Specific binding members for TGFbeta1
12/10/2002	US6492495 PTP-S31: a novel protein tyrosine phosphatase
12/10/2002	US6492343 Porcine adenovirus type 3 genome
12/10/2002	US6492337 Administering a ceramide
12/10/2002	US6492331 NL8 tie ligands homologues
12/10/2002	US6492325 Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
12/10/2002	US6492167 Membrane protein for use in the treatnment of diabetes, hypotension, endocrine defects
12/10/2002	US6492157 Methods are provided for the treatment of conditions associated with cells proliferation, cells differentiation and cell survival. in particular, the dual-specificity phosphatase dsp-9, and polypeptide variants thereof that
12/10/2002	US6492148 A method for the preparation of an infectious ibdv mutant which will replicate in cef cell culture, comprising: separately preparing a dna construct comprising cdna of genome segments a and b of an ibdv which is not capable of
12/10/2002	US6492145 Vaccine against mycobacterial infections
12/10/2002	US6492131 Class I-type lysyl-TRNA synthetase
12/10/2002	US6492129 Fragments comprising the n-terminal region of connective tissue growth factor (ctgf); screening for inhibitors or stimulators of ctgf
12/10/2002	US6492126 Compositions and methods for the treatment and diagnosis of cardiovascular disease
12/10/2002	US6491956 Food containing active strains for inhibiting infection and treating gastritis, gastric and duodenal ulcers
12/10/2002	US6491926 35 kD tumor associated protein antigen: uses and methods of detection
12/10/2002	US6491925 Compositions and methods for cancer prophylaxis and/or treatment
12/10/2002	US6491924 Sequence of at least 5 consecutive amino acids in the polypeptide of seq id no: 1
12/10/2002	US6491921 Nucleic acids immunology vectors comprising eukaryotic transcription or translation gene expression controllers having enhancers and codes for immunogen polypeptides used against infections
12/10/2002	US6491920 Polypeptides and DNA encoding same
12/10/2002	US6491919 Attenuated lipid and surfactant in aqueous solution
12/10/2002	US6491915 Anti-CCR2 antibodies and methods of use therefor
12/10/2002	US6491914 Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions including the anti-idiotypic monoclonal antibodies
12/10/2002	US6491908 Selective elimination of T cells that recognize specific preselected targets
12/10/2002	US6491907 Genetic engineered chimera particles comprising capsids from adeno-associated virus and genome inverted terminal repeat sequences as vectors for supplying and expressing nucleotide sequence in cells
12/10/2002	CA2196085C Mhc complexes and uses thereof
12/10/2002	CA2114015C Recombinant antibodies for human therapy
12/10/2002	CA2047290C Recombinant marek's disease virus
12/10/2002	CA2038423C Process for preparing a purified treponemal antigen and use thereof
12/10/2002	CA1341407C Minactivin
12/08/2002	CA2817619A1 Methods of administering anti-tnf.alpha. antibodies
12/08/2002	CA2386262A1 Method for nasal application of a medicinal substance
12/08/2002	CA2385745A1 Methods of administering anti-tnf.alpha. antibodies
12/07/2002	CA2386356A1 Ligation of ceacam1
12/06/2002	CA2349748A1 Therapeutic uses of glandular kallikrein
12/05/2002	WO2002097395A2 P-cadherin as a target for anti-cancer therapy
12/05/2002	WO2002097120A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	WO2002097091A1 Generation of hcv-like particles and chimeric hcv virus
12/05/2002	WO2002097081A2 Method to generate non virulent microorganisms from pathogenic ones trough permanent genetic modification of their biological membrane for vaccine production
12/05/2002	WO2002097072A2 Influenza vaccine composition
12/05/2002	WO2002097051A2 Protein arrays and methods and systems for producing the same
12/05/2002	WO2002097048A2 ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
12/05/2002	WO2002097044A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	WO2002097041A2 Fusion proteins of biologically active peptides and antibodies
12/05/2002	WO2002097035A2 Secreted proteins
12/05/2002	WO2002097034A2 Antibodies and antigens of hiv viremia controllers
12/05/2002	WO2002097033A2 Antibodies that immunospecifically bind to trail receptors
12/05/2002	WO2002097032A2 Proteins associated with cell growth, differentiation, and death
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096951A1 Molecules for disease detection and treatment
12/05/2002	WO2002096949A1 Antigen targeting
12/05/2002	WO2002096942A2 Recombinant dna encoding the major allergen of plantago lanceolata pollen pla l 1, and applications thereof
12/05/2002	WO2002096941A2 Polypeptide which reacts with the antibodies of patients infected by hcv and uses thereof
12/05/2002	WO2002096940A2 Attenuated very virulent infectious bursal disease virus
12/05/2002	WO2002096937A2 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096929A2 Polypeptides reacting with hcv-infected patients' antibodies and uses
12/05/2002	WO2002096923A1 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
12/05/2002	WO2002096910A1 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
12/05/2002	WO2002096458A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	WO2002096457A2 Stable liquid formulations of antibodies
12/05/2002	WO2002096456A1 Use of il-18 inhibitors for treating or preventing cns injuries
12/05/2002	WO2002096455A2 Use of polyclonal immunoglobulins
12/05/2002	WO2002096407A1 Liquid drug preparations
12/05/2002	WO2002096386A1 Solid form immunity adjuvant and vaccine containing same
12/05/2002	WO2002096350A2 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
12/05/2002	WO2002096349A2 Vaccination against the feline immunodeficiency virus
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002064757A3 Influenza viruses with enhanced transcriptional and replicational capacities
12/05/2002	WO2002060924A9 Identification and applications of porcine reproductive and respiratory syndrome virus host susceptibility factor(s) for improved swine breeding and development of a non-simian recombinant cell line for propagation of the virus and a target for a novel class of antiviral compounds
12/05/2002	WO2002059155A3 Modulation of calcium channel activity
12/05/2002	WO2002059146A3 Peptides having affinity for the gp120 viral protein and use thereof
12/05/2002	WO2002055675A8 Ancillary composition for the preparation of committed mature dendritic cells
12/05/2002	WO2002047728A3 Treatment of posterior capsule opacification
12/05/2002	WO2002040511A3 Dna sequence and microcine from escherichia coli strain dsm 6601
12/05/2002	WO2002028351A9 Recombinant mucin binding proteins from steptococcus pneumoniae
12/05/2002	WO2002016413A3 Cripto tumour polypeptide
12/05/2002	WO2002013862A3 Method and composition for altering a b cell mediated pathology
12/05/2002	WO2002013861A3 Method and composition for altering a t cell mediated pathology
12/05/2002	WO2002006453A3 Regulation of human desc1-like serine protease
12/05/2002	WO2001097608A3 Cyk-4 polypeptides, dna molecules encoding them and their use in screening methods
12/05/2002	WO2001096391A3 55p4h4: gene expressed in various cancers
12/05/2002	WO2001088085A3 Novel bee venom polypeptides and methods of use thereof
12/05/2002	WO2001085947A3 Compounds and methods for the diagnosis and treatment of babesia microti infection
12/05/2002	WO2001064949B1 Diagnostics and therapeutics for glaucoma
12/05/2002	WO2001060397A9 Uses of agonists and antagonists to modulate activity of tnf-related molecules
12/05/2002	WO2001044816A9 Conformational and topological protein regulation
12/05/2002	WO2001034193A9 Plant lectins as mucosal adjuvants
12/05/2002	WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
12/05/2002	WO2001021796A9 Gl50 molecules and uses therefor
12/05/2002	WO2001019958A9 Stabilized soluble glycoprotein trimers

1 ... 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 ... 1823